This content is machine translated Underestimated risk - findings from a US cohort Heart failure after myocardial infarction Acute myocardial infarction is now considered more treatable than ever. However, despite optimized reperfusion, modern pharmacotherapies and improved care systems, one risk remains that is underestimated in many clinical procedures:...…
View Post 9 min This content is machine translated Evidence, pathophysiology and management in the light of current data Heart failure with improved ejection fraction (HFimpEF) In recent years, Heart Failure with Improved Ejection Fraction (HFimpEF) has developed into a clinical entity in its own right, which is being considered in an increasingly differentiated manner. With...…
View Post 4 min This content is machine translated Sudden cardiac death after myocardial infarction New perspectives for risk stratification and prevention Sudden cardiac death (SCD) is one of the leading causes of death worldwide and is particularly common in patients who have survived a myocardial infarction (MI). Despite significant advances in…
View Post 3 min This content is machine translated Heart failure in the light of the latest evidence MRAs offer advantages across the entire EF spectrum At the swissESCupdate, cardiology experts summarized important content from this year’s Annual Meeting of the European Society of Cardiology . In the area of heart failure, studies on the use…
View Post 8 min This content is machine translated Heart failure Ejection fraction as a therapy criterion Heart failure with reduced ejection fraction (HFrEF) is characterized by a left ventricular ejection fraction (LVEF) in the range ≤40% according to the current classification, whereas heart failure with preserved…
View Post 8 min This content is machine translated Heart failure update Which drugs for which patients? The new guidelines for the diagnosis and treatment of heart failure were presented at this year’s congress of the European Society of Cardiology at the end of May. The new…
